Spring Co-Op, Oncology Research In Vivo Discovery
Boehringer Ingelheim
Summary
Boehringer Ingelheim is currently seeking a talented and innovative Co-Op student in Spatial Biology to join our Oncology Research – Oncology Pharmacology and Disease Modeling team located at our Ridgefield, CT facility.
Job description
The Co-Op will contribute to both the experimental generation and computational analysis of spatial biology data to characterize preclinical oncology models and their relationship to human disease. The project will combine spatial transcriptomics, multiplex tissue imaging, image analysis, and cross-species approaches to investigate cellular composition, molecular states, and spatial organization within the tumor microenvironment.
This internship is ideally suited for a PhD student interested in working at the interface of tumor biology, spatial technologies, quantitative imaging, and computational analysis.
Duties & Responsibilities
- Perform spatial biology experiments using human and mouse tissues, including staining, assay execution, imaging, and experimental QC
- Support optimization and implementation of spatial transcriptomic and high-plex protein imaging workflows, including tissue- and assay-specific optimization
- Analyze spatial transcriptomic and multiplex imaging datasets, including data QC, visualization, cell/tissue annotation, segmentation, phenotyping, and spatial analysis
- Integrate spatial RNA, protein imaging, and histopathology data to characterize tissue architecture, cellular phenotypes, and spatial relationships
- Apply cross-species approaches to compare mouse tumor models with human disease and identify conserved and divergent biological features
- Collaborate with scientists across in vivo pharmacology, pathology, translational research, spatial biology, and computational sciences to interpret results and communicate findings
Desired Skills, Experience and Abilities
- Experience analyzing single-cell and/or spatial transcriptomic data using R or Python
- Experience with or strong interest in digital pathology, multiplex imaging, quantitative image analysis, or spatial statistics
- Familiarity with computational tools or frameworks for single-cell/spatial analysis and image analysis
- Strong interest in tumor microenvironment biology and cross-species modeling
- Ability to critically interpret complex biological datasets and communicate findings to both computational and experimental scientists
Requirements
- Must be a current graduate or advanced degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the co-op
- Overall cumulative minimum GPA from last completed quarter/semester 3.0 GPA (on a 4.0 scale) preferred
- Major or minor in related field of co-op
- Undergraduate students must have completed at least 12 credit hours at current college or university
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
- Experience analyzing single-cell and/or spatial transcriptomic data using R or Python
- Experience with or strong interest in digital pathology, multiplex imaging, quantitative image analysis, or spatial statistics
- Familiarity with computational tools or frameworks for single-cell/spatial analysis and image analysis
- Strong interest in tumor microenvironment biology and cross-species modeling
- Ability to critically interpret complex biological datasets and communicate findings to both computational and experimental scientists
Benefits
- Medical Coverage
- Paid Time Off
- Paid Holidays
- Disability Insurance
- Life Insurance
- Company-Sponsored Benefits
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.